We’re Hiring! View Open Positions

Archives

Last 20 Posts

 
  1. Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
  2. Enzyvant Announces Merger with Altavant
  3. 43rd Annual Meeting & Scientific Sessions of the ISHLT
  4. Alliance for Regenerative Medicine (ARM) Cell & Gene Meeting on the Mediterranean
  5. ACC.23 Together With WCC
  6. PCMA Business Forum 2023
  7. American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting 2023
  8. 45th Annual Pulmonary and Allergy Update
  9. American Thoracic Society (ATS) 2022
  10. Altavant Sciences Presents Data Showing Potential for Combination of Rodatristat Ethyl and Ambrisentan in Model of Pulmonary Arterial Hypertension
  11. Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
  12. International Society for Heart & Lung Transplantation (ISHLT)
  13. Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
  14. Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
  15. SCOPE Europe 2022
  16. Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant
  17. Enzyvant Appoints Johanna Rossell as Chief Commercial Officer
  18. Altavant Sciences Highlights Ongoing Phase 2b ELEVATE 2 Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at European Respiratory Society Annual Congress
  19. European Respiratory Society International Congress 2021
  20. Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)

By Month

 

Contact us for more information

Contact Us